The FDA has granted expanded the use of Eylea injection to treat diabetic retinopathy in patients with diabetic macular edema (DME).
Both bariatric surgery and intensive weight management yielded similar improvements in HbA1c, weight loss and quality of life.
Only two states, New Jersey and Massachusetts, have ruled on patients' rights in a non-compete situation thus far.
For every 30 minutes of lost weekday sleep, the risk of obesity and insulin resistance increased substantially.
Providers may have not made changes to treatment strategies due to the high effectiveness of biologics in most visits.